Equilis West Nile

RSS

inactivated chimaeric flavivirus strain YF-WN

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This summary cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 15/10/2018

Authorisation details

Product details
Name
Equilis West Nile
Agency product number
EMEA/V/C/002241
Active substance
inactivated chimaeric flavivirus strain YF-WN
International non-proprietary name (INN) or common name
inactivated chimaeric flavivirus strain YF-WN
Species
Horses
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI05AA10
Publication details
Marketing-authorisation holder
Intervet International BV
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
06/06/2013
Contact address
Wim de Körverstraat 35
5831 AN Boxmeer
Netherlands

Product information

03/10/2018 Equilis West Nile - EMEA/V/C/002241 - IB/0006

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals

Therapeutic indication

Active immunisation of horses against West Nile virus (WNV) to reduce clinical signs of disease and lesions in the brain and to reduce viraemia.

Onset of immunity: 2 weeks after primary vaccination course of two injections.

Duration of immunity: 12 months.

Assessment history

How useful was this page?

Add your rating